膀胱肿瘤细胞多药耐药检测在浸润性膀胱肿瘤治疗中的应用-东南大学学报医学版

膀胱肿瘤细胞多药耐药检测在浸润性膀胱肿瘤治疗中的应用

单位：南京医科大学附属常州第二医院,泌尿外科,江苏,常州,213003

分类号：R737.14

出版年·卷·期（页码）：2005·24·第六期（374-376）

摘要：

目的:检测膀胱肿瘤细胞多药耐药情况,以选择敏感药物治疗浸润性膀胱肿瘤.方法:双侧髂内动脉灌注化疗前采用免疫组织化学方法对10例膀胱肿瘤病例作多药耐药糖蛋白(P-gp)、谷胱甘肽S转移酶(GST-p)和拓扑异构酶Ⅱ(TopoⅡ)表达情况检测.结果:灌注前P-gp的表达率为30%,GST-p为10%,TopoⅡ为50%.灌注药物选择吡柔比星、顺铂和羟基喜树碱.灌注后P-gp的表达率为50%,GST-p为10%,TopoⅡ为40%.结论:检测P-gp、GST-p、TopoⅡ表达情况对浸润性膀胱肿瘤化疗药物的选择具有重要意义.

Objective To detect multidrug resistance in bladder tumor,thus to select sensitive drugs to treat invasive bladder tumor.Method In 10 cases of bladder tumors,P-gp,GST-p and TopoⅡ were detected by immunohistochemistry technique before intra-arterial chemotherapy.Results Before intra-arterial chemotherapy the expression rate of P-gp was 30%,GST-p was 10%,Topo Ⅱ was 50%.Chemotherapy drug were THP,DDP and HCPT.After intra-arterial chemotherapy,the expression rate of P-gp was 50%,GST-p was 20%,Topo Ⅱ was 40%,respectively.Conclusion Detection of P-gp,GST-p and Topo Ⅱ play a role in selection of drug in invasive bladder tumor.

参考文献：

[1] 吴小鹏, 陆曙炎, 邹建纲. 浸润性膀胱肿瘤的治疗. 北京医药2003(4). doi:10.3969/j.issn.0253-9713.2003.04.009
[2] 李鸣, 李宁忱, 黄真. 浸润性膀胱癌术前选择性髂内动脉灌注化疗的近远期疗效观察. 中华泌尿外科杂志2004(10)
[3] DASCHNER P J, CIOLINO H P, PLOUZEK C A. Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells. 1999. doi:10.1023/A:1006138803392
[4] ENOKIDA H, GOTANDA T, OKU S. Reversal of P-glycoprotein-mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line. 2002
[5] 陈传忠, 黄勤, 陈仕平. DNA拓扑异构酶Ⅱ与多药耐药研究进展, 1998

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录